Eltrombopag: all 135 studies that test it
Page 2 of 2. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- Eltrombopag in Second Line Adult Primary Immune ThrombosytopeniaCompletedNCT02402998Phase 2
- A Study of Eltrombopag in Patients With CMML and ThrombocytopeniaCompletedNCT02323178Phase 1/2
- Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy SubjectsCompletedNCT02281370Phase 1
- A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting ConditionsCompletedNCT02254434Phase 1
- hATG+CsA vs hATG+CsA+Eltrombopag for SAACompletedNCT02099747Phase 3
- A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced ThrombocytopeniaStatus unknownNCT02093325Phase 3
- Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood TransplantationStatus unknownNCT01940562Phase 2
- Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.CompletedNCT01791101Phase 2
- Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood TransplantationStatus unknownNCT01757145Phase 2
- Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult SubjectsCompletedNCT01657552Phase 1
- Eltrombopag and High-dose Dexamethasone as First Line Treatment for ITCompletedNCT01652599Phase 2
- A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia PatientsCompletedNCT01621204Phase 3
- Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)CompletedNCT01610180Phase 2
- Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid LeukemiaTerminatedNCT01550185Phase 1
- A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)TerminatedNCT01500538Phase 2
- Eltrombopag for the Prevention of Chemotherapy Induced ThrombocytopeniaTerminatedNCT01491594Phase 1
- A Single Arm Pilot Study of Azacitidine in Myelodysplastic Syndromes (MDS) / Acute Myeloid Leukaemia (AML), With Eltrombopag Support for ThrombocytopeniaCompletedNCT01488565Phase 2
- Safety Study of Eltrombopag Combined With Azacitidine to Treat Myelodysplastic Syndrome (MDS)CompletedNCT01481220Phase 1
- Eltrombopag in Thrombocytopenic Chronic Lymphocytic Leukemia (CLL) Patients (CLL2S Study of GCLLSG)TerminatedNCT01397149Phase 1/2
- Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCTCompletedNCT01286675Early Phase 1
- Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With ThrombocytopeniaTerminatedNCT01286038Phase 1
- Study of Eltrombopag in Platelet Refractory ThrombocytopeniaWithdrawnNCT01194167Phase 2
- Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food EffectCompletedNCT01072162Phase 1
- Milk-only Lactation Study for Patients on EltrombopagWithdrawnNCT01055600Phase 4
- Eltrombopag Treatment of Thrombocytopenia in Subjects With Advanced Myelodysplastic Syndrome (MDS) or Secondary Acute Myeloid Leukemia After MDS (sAML/MDS)CompletedNCT00903422Phase 1
- Platelet Function in Idiopathic Thrombocytopenic Purpura (ITP) Patients With EltrombopagCompletedNCT00888901Phase 4
- Drug Interaction Study Between Eltrombopag and Lopinavir/Ritonavir in Healthy Adult Subjects.CompletedNCT00833378Phase 1
- Study In Healthy Subjects To Evaluate The Photo-Irritant Potential Of EltrombopagCompletedNCT00688272Phase 1
- Eltrombopag Taste Testing in Healthy Adult VolunteersCompletedNCT00487968Phase 1
- Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal ImpairmentCompletedNCT00442871Phase 1
- Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic ImpairmentCompletedNCT00359463Phase 1
- Dose Finding Study Of Oral Eltrombopag In Patients With Sarcoma Receiving Adriamycin And IfosfamideCompletedNCT00358540Phase 1
- SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis CCompletedNCT00110799Phase 2
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP)CompletedNCT00102739Phase 2
- SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving ChemotherapyCompletedNCT00102726Phase 2